In short
- FDA-approved peptides such as Vyleesi and Egrifta SV have known risks listed on their labels: 40% of women in Vyleesi’s trials had nausea, for example.
- For BPC-157, the FDA says it has no, or only limited, safety information for the routes people use. For TB-500, KPV and MOTS-c it has found no human exposure data at all.
- The FDA reports serious adverse events with CJC-1295 (including increased heart rate) and with ipamorelin (including death when given into a vein).
- Vials sold online for research only are unapproved and unregulated, and buying them for personal use is unsafe: no one checks what is inside.
- A licensed prescriber, a pharmacy you can verify with your state board and LegitScript certification are the three checks worth making before you pay.
Whether a peptide is safe depends less on the word “peptide” than on which peptide it is and where it came from. FDA-approved peptides have known risks printed on their labels. Peptides compounded by a licensed pharmacy for your prescription aren’t FDA-reviewed, but you know what you were prescribed and a clinician is watching for problems. Vials sold online for research, with no prescription, have neither, and buying them for personal use is unsafe and unregulated. Here is what the FDA has found and how to lower your risk.
Three kinds of peptide, three levels of risk
| Source | What you know about it | Main risks |
|---|---|---|
| FDA-approved drug (Vyleesi, Egrifta SV, Wegovy) | Tested in controlled trials; ingredients, dose and side effects on the label | The labeled side effects and warnings |
| Compounded by a licensed pharmacy for your prescription (sermorelin, PT-141, oxytocin, topical GHK-Cu) | Prepared for you by a licensed pharmacy; not FDA-reviewed for safety, effectiveness or quality | Limited evidence for off-label uses; quality depends on the pharmacy |
| Sold online for research, without a prescription | Nothing verified: identity, strength and sterility are unknown | Contamination, wrong or missing ingredient, wrong dose, no medical oversight |
What the FDA says about popular peptides
The FDA keeps a page summarizing safety concerns for substances nominated for compounding (FDA). None of these can be compounded by a 503A pharmacy as of October 18, 2026. In the FDA’s own words:
| Peptide | What the FDA says |
|---|---|
| BPC-157 | “No, or only limited, safety-related information for the proposed routes of administration” |
| TB-500 | Has “not identified any human exposure data” on drug products containing it |
| KPV | Has “not identified any human exposure data on drug products containing KPV” |
| MOTS-c | Has “not identified any human exposure data on drug products containing MOTs-C” |
| CJC-1295 | “Serious adverse events associated with CJC-1295 including increased heart rate” |
| Ipamorelin | “Serious adverse events including death when ipamorelin was administered intravenously” |
| AOD-9604 | “Serious adverse events that may be associated with AOD-9604, though causality is not clear” |
| LL-37 | “Nonclinical research findings suggest detrimental effects on male reproduction” |
| GHK-Cu, injectable | “There are limited data in humans to inform safety-related considerations” |
| Kisspeptin-10 | “No, or only limited, safety-related information for the proposed routes of administration” (still in Category 2) |
“No human exposure data” means the FDA couldn’t find information on what happens when people take these products. That isn’t proof of harm, but it means nobody can tell you the risks.
The risks of gray-market vials
Online shops sell many of these peptides as research chemicals, with labels saying they are for laboratory research only. Buying them for personal use is unsafe and unregulated, for four reasons.
You don’t know what’s in the vial. No licensed pharmacy prepared it, and no one has verified that it contains the peptide on the label, at the stated amount, without other substances.
Injections need to be sterile. Most of these products are injected under the skin. A product made without sterile controls can carry bacteria or toxins that cause infections or reactions.
No one is checking whether it suits you. A prescription comes with a clinician who reviews your health history, your other medications and warning signs. A research vial comes with none of that.
There’s no recourse. If something goes wrong, there is no prescriber to call and no pharmacy accountable for the product. The FDA treats these products as unapproved new drugs: it sent warning letters over BPC-157 and TB-500 sold this way in June 2023, and over retatrutide and cagrilintide as recently as March 31, 2026.
Known risks of the peptides you can be prescribed
Lawful peptides have side effects too, and some are serious. These come from FDA labels.
PT-141 (bremelanotide). In the trials behind Vyleesi, 40% of women had nausea (vs 1.3% on placebo), 20% flushing and 11% headache. Each dose briefly raises blood pressure by up to 6/3 mmHg, so it is not for people with uncontrolled high blood pressure or known heart disease. It can sharply lower the levels of oral naltrexone (label). See our bremelanotide guide.
Tesamorelin (Egrifta SV). It can raise blood sugar: 5% of patients reached an HbA1c of 6.5% or higher, vs 1% on placebo. The label also warns of fluid retention, joint pain, carpal tunnel syndrome and allergic reactions, and rules it out in pregnancy and active cancer (label). See our tesamorelin guide.
Oxytocin. It makes the uterus contract, so it is not for use in pregnancy outside a hospital. The injection label warns of severe water intoxication with seizures and coma (label). Compounded sprays and troches for stress or sleep are off-label. See our oxytocin guide.
Sermorelin. It raises your own growth hormone. Hone Health’s sermorelin page, for example, flags a history of cancer, diabetes or untreated thyroid problems as reasons to talk to a clinician first. See is sermorelin legal and how is it prescribed.
Topical GHK-Cu. Redness, tingling, dryness and irritation are the usual complaints, more often alongside retinoids or exfoliating acids. See our GHK-Cu guide.
Compounded isn’t the same as unregulated
A compounded peptide from a licensed pharmacy sits between an approved drug and a research vial. The FDA doesn’t review it before it is sold, so its safety and effectiveness for your use haven’t been tested the way an approved drug’s have. But the pharmacy is licensed by its state, it prepares the medicine for your prescription, and under the FDA’s interim policy the bulk ingredient for a Category 1 substance has to come from an FDA-registered manufacturer with a valid certificate of analysis.
Quality still varies from pharmacy to pharmacy, so it is fair to ask your provider:
- Which pharmacy fills the prescription, and is it a licensed 503A pharmacy?
- Where does the pharmacy get the peptide, and does each lot come with a certificate of analysis?
- Does the pharmacy test injectables for sterility and endotoxins? Eden, for example, says its pharmacies test every compounded lot for sterility and endotoxins and check potency every 3 to 6 months.
A provider that can’t answer these questions is telling you something.
How to lower your risk
- Use a licensed provider. A licensed clinician should review your history before prescribing, and you should be able to message them afterwards.
- Know your pharmacy. Ask which pharmacy fills your prescription, then check its license with your state board of pharmacy. PepScribe, for example, lists its three 503A pharmacies with NPI numbers so you can look them up.
- Check certification. LegitScript certifies online pharmacies and telehealth providers; a certified provider will show a seal you can verify.
- Stick to peptides a pharmacy may compound. If a provider offers BPC-157, TB-500, CJC-1295 or ipamorelin as a prescription, that is a warning sign. See are peptides legal in 2026.
- Share everything. Tell your clinician about every medication and supplement, including other peptides.
- Report problems. Tell your clinician about side effects, and report serious reactions to the FDA through MedWatch.
Red flags
- Vials labeled for research, or “not for human use”, sold with dosing guides.
- No prescription, no clinician and no health questions.
- A “stack” of several peptides, some of which pharmacies may not compound.
- Claims that a peptide is safe because it is “natural” or “made by the body”.
- No named pharmacy, or a refusal to tell you who fills prescriptions.
The bottom line
Peptides aren’t safe or unsafe as a group. FDA-approved ones have known, labeled risks; lawfully compounded ones come from a licensed pharmacy with a clinician involved, though their off-label uses aren’t FDA-reviewed; and gray-market vials sold for research are unknown quantities that are unsafe to use. If you want peptide therapy, compare the licensed providers in our ranked list, where every listing is checked for a licensed prescriber and lawful peptides only, or start at the peptides hub.
Questions, answered
Are peptides safe to inject?
Is BPC-157 safe?
What are the side effects of PT-141?
How do I report a bad reaction to a peptide?
Sources
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026)
- FDA: Bulk drug substances nominated for use in compounding under section 503A (categories list, updated May 14, 2026)
- Vyleesi (bremelanotide) prescribing information, DailyMed
- Egrifta SV (tesamorelin) prescribing information, DailyMed
- Pitocin (oxytocin injection) prescribing information, DailyMed
- FDA warning letter on BPC-157 and TB-500 sold for research (Jun 12, 2023)
- FDA warning letter on retatrutide and cagrilintide sold for research (Mar 31, 2026)
- FDA: MedWatch safety information and adverse event reporting program
- PepScribe: Pharmacy and clinical partners (read Oct 18, 2026)